Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Calpain inhibitors reported by Warner-Lambert

Oct. 11, 1996

New muscarinic antagonists from Schering-Plough

Oct. 11, 1996

Copaxone approvable for MS

Oct. 11, 1996

FDA approval for Taro generic drug

Oct. 11, 1996

First launch for olanzapine

Oct. 11, 1996

Potential antipsychotic agents disclosed by Pharmacia & Upjohn

Oct. 11, 1996

Dopamine D3 ligands from Pharmacia & Upjohn

Oct. 11, 1996

New dopamine receptor ligands reported by Neurogen

Oct. 11, 1996

Suntory reports agents for CNS and cerebrovascular disorders

Oct. 11, 1996

Hypnotic agent in the Fujisawa pipeline

Oct. 11, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...